Caladrius Biosciences Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
Caladrius Biosciences Inc. (0HS8) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2021: -0.051x
Based on the latest financial reports, Caladrius Biosciences Inc. (0HS8) has a cash flow conversion efficiency ratio of -0.051x as of September 2021.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.04 Million) by net assets ($98.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Caladrius Biosciences Inc. - Cash Flow Conversion Efficiency Trend (2016–2020)
This chart illustrates how Caladrius Biosciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Caladrius Biosciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caladrius Biosciences Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Rakyat Indonesia Agroniaga
JK:AGRO
|
0.177x |
|
LWSABAH
KLSE:5328
|
N/A |
|
Duksung
KO:004830
|
0.014x |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
-0.010x |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
-0.650x |
|
GUNOSY INC.
F:6GU
|
N/A |
|
PT Wintermar Offshore Marine Tbk
F:W6O
|
0.027x |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
-0.195x |
Annual Cash Flow Conversion Efficiency for Caladrius Biosciences Inc. (2016–2020)
The table below shows the annual cash flow conversion efficiency of Caladrius Biosciences Inc. from 2016 to 2020.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2020-12-31 | $32.50 Million | $-8.82 Million | -0.272x | +70.07% |
| 2019-12-31 | $20.82 Million | $-18.88 Million | -0.907x | -71.22% |
| 2018-12-31 | $37.73 Million | $-19.99 Million | -0.530x | -28.17% |
| 2017-12-31 | $50.51 Million | $-20.88 Million | -0.413x | +91.47% |
| 2016-12-31 | $4.88 Million | $-23.67 Million | -4.846x | -- |